WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 49.63 CNY -5.59% Market Closed
Market Cap: 124.1B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

WuXi AppTec Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Total Receivables
ÂĄ10.1B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Receivables
ÂĄ2.9B
CAGR 3-Years
23%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Receivables
ÂĄ6.8B
CAGR 3-Years
13%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Receivables
ÂĄ4.3B
CAGR 3-Years
31%
CAGR 5-Years
31%
CAGR 10-Years
33%
M
MGI Tech Co Ltd
SSE:688114
Total Receivables
ÂĄ931.5m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Receivables
ÂĄ985.8m
CAGR 3-Years
177%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
124.1B CNY
Industry
Life Sciences Tools & Services

WuXi AppTec Co., Ltd. is a prominent global healthcare platform that plays a pivotal role in empowering the pharmaceutical, biotechnology, and medical device industries. Founded in 2000 and headquartered in Shanghai, WuXi has cultivated a reputation for excellence through its extensive suite of services, which span the entire drug development lifecycle. From drug discovery to manufacturing, the company leverages cutting-edge technologies and a rich network of expertise to facilitate the development of innovative therapeutics. This comprehensive capability enables WuXi to serve as a trusted partner for clients, helping to streamline the complex path from concept to commercialization. With a focus on innovation and quality, WuXi AppTec has distinguished itself in the competitive landscape of contract research organizations (CROs) and contract manufacturing organizations (CMOs). The company's robust growth trajectory is underpinned by strategic investments in technology and infrastructure, as well as a commitment to expanding its global footprint. WuXi's expansive service offerings not only enhance operational efficiency for its partners but also align with the increasing demand for faster and more cost-effective drug development solutions. For investors, WuXi signifies an opportunity to engage with a market leader poised to capitalize on the burgeoning biopharmaceutical sector, driven by rising global healthcare needs and transformative advancements in science and technology.

Intrinsic Value
88.5 CNY
Undervaluation 44%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Total Receivables?
Total Receivables
10.1B CNY

Based on the financial report for Jun 30, 2024, WuXi AppTec Co Ltd's Total Receivables amounts to 10.1B CNY.

What is WuXi AppTec Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
29%

Over the last year, the Total Receivables growth was -1%. The average annual Total Receivables growth rates for WuXi AppTec Co Ltd have been 23% over the past three years , 29% over the past five years .

Back to Top